The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity

International Journal of Immunopharmacology

Volumn 17, Issue 10, 1995, Pages 793-803

  Sullivan, Gail W ^a   Carper, Holliday T ^a   Mandell, Gerald L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

adenosine; neutrophil; phosphodiesterase; rolipram; superoxide; tumor necrosis factor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DEAMINASE; CHEMOATTRACTANT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FIBRINOGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; KT 5720; PENTOXIFYLLINE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROTEIN KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ROLIPRAM; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; WRC 0474;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; NEUTROPHIL; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY BURST; SEPSIS; TISSUE INJURY;

ADENOSINE; DRUG SYNERGISM; HUMAN; IN VITRO; INDOLES; NEUTROPHILS; PENTOXIFYLLINE; PHENETHYLAMINES; PHOSPHODIESTERASE INHIBITORS; PYRROLES; PYRROLIDINONES; RESPIRATORY BURST; ROLIPRAM; SUPEROXIDES; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0028835052     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/0192-0561(95)00073-B     Document Type: Article

References (72)

1. Differential effects of hydrogen peroxide on indices of endothelial cell function
2. Recombinant human tumor necrosis factor-alpha: regulation of N-formylmethionylleucyphenylalanine receptor affinity and function on human neutrophils
3. Influence of improved tissue oxygenation on plasma adenosine (ADO) in septic patients
4. Influence of pentoxifylline and related analogues in endotoxemic renal failure
5. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor
6. The role of adenosine in the regulation of coronary blood flow
7. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells
8. Purification ofcachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells
9. 558 of NADPH oxidase by phosphorylation of Rap1A
10. Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis
11. Gammaflow: a completely automated radioimmunoassay system
12. αs-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil
13. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization
14. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils
15. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils
16. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biologic surfaces
17. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators
18. Interleukin-1
19. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells
20. Effects of tumor necrosis factor alpha and interleukin-1-alpha and beta on human neutrophil migration, respiratory burst and degranulation
21. Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method
22. Regulation of neutrophil migration and superoxide production by recombinant tumor necrosis factors-α and -β comparison to recombinant interferon-γ and interleukin-1α
23. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice
24. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response
25. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
26. rTNF-a facilitates human polymorphonuclear leukocyte adherence to fibrinogen matrices with mobilization of specific and tertiary but not azurophilic granule markers
27. Modulation of TNF, IL-1 and IL-6 secretion by anthrax toxin
28. Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine
29. Effects of adenosine on human neutrophil function and cyclic AMP content
30. 2 receptors in rat brain
31. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases
32. Stimulation of neutrophils by tumor necrosis factor
33. Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice
34. Pharmacokinetics of the antidepressant rolipram in healthy volunteers
35. Tumor necrosis factor a cytokine involved in toxic effects of endotoxin
36. Gram-negative sepsis and the adult respiratory distress syndrome
37. Pentoxifylline reduces injury to isolated lungs perfused with human neutrophils
38. Inhibition of tumor necrosis factor a secretion from endotoxin stimulated human monocytes by WAY-PDA-641 and rolipram
39. Tumor necrosis factor and CD11/CD18(β2) integrins act synergistically to lower cAMP in human neutrophils
40. Role of myeloperoxidase in the respiratory burst of human neutrophils
41. Effects of adenosine on polymorphonuclear leucocyte function, cyclic 3′:5′-adenosine monophosphate, and intracellular calcium
42. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst
43. 2-(N'-aralkylidenehydrazineo)adenosines: potent and selective coronary vasodilators
44. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-a production and protect mice against endotoxin challenge
45. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides
46. Pentoxifylline lessens the endotoxin-induced increase in albumin clearance across pulmonary artery endothelial monolayers with and without neutrophils
47. Mechanisms of tumor necrosis factor-α alternation of PMN adhesion and migration
48. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages
49. Stereospecific binding of the antidepressant rolipram to brain protein structures
50. The effects of adenosine agonists on human neutrophil function
51. The specific type IV phosphosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
52. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha
53. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues
54. Adenosine inhibits platelet-activating factor, but not tumor necrosis factor-α induced priming of human neutrophils
55. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline
56. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline
57. Pentoxifylline inhibits the inflammatory effects of endotoxin and endotoxin-induced cytokines on neutrophil function
58. Adenosine and related compounds counteract tumor necrosis factor-α inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface
59. Enhancement of chemotaxis and protection of mice from infection
60. Role of phosphodiesterase in the regulation of endothelial permeability in vitro
61. Activation of neutrophils by cachectin/tumor necrosis factor: priming of N-formyl-methionyl-leucyl-phenylalanine-induced oxidative responsiveness via receptor mobilization without degranulation
62. Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model
63. Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome
64. Therapeutic intervention in a rat model of ARDS: phosphodiesterase IV inhibition
65. 2 adenosine receptors
66. The extinction coefficient of cytochrome c
67. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees
68. Potential antidepressant activity of rolipram and other 3', 5'-monophosphate phosphodiesterase inhibitors
69. Pentoxifylline in septic shock
70. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog
71. Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase
72. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence